Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Hodgkin Disease 77Lymphoma 34Lymphoma, Large-Cell, Anaplastic 24Hematologic Diseases 20Recurrence 16Lymphoma, Non-Hodgkin 16Lymphoma, T-Cell 13Lymphoma, T-Cell, Peripheral 12Lymphoma, T-Cell, Cutaneous 12Lymphoma, Large B-Cell, Diffuse 10Mycosis Fungoides 9Sezary Syndrome 5Neoplasms 5Lymphoma, B-Cell 5Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphomatoid Papulosis 4Lymphoma, Primary Cutaneous Anaplastic Large Cell 4Lymphatic Diseases 4Leukemia, Myeloid, Acute 4Immunoblastic Lymphadenopathy 4Enteropathy-Associated T-Cell Lymphoma 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms, Germ Cell and Embryonal 3Lymphoma, Follicular 3Leukemia 3Dendritic Cell Sarcoma, Interdigitating 3Testicular Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Neoplasms by Histologic Type 2Myelodysplastic Syndromes 2

Interventions

Cisplatin 10Ifosfamide 9Etoposide 9Paclitaxel 8Filgrastim 8Carboplatin 7Bleomycin 7Peripheral Blood Stem Cell Transplantation 4pegfilgrastim 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Granulocyte Colony-Stimulating Factor 3liposomal amphotericin B 2Thiotepa 2Therapeutics 2Specimen Handling 2Mesna 2Cyclophosphamide 2Brentuximab Vedotin 2sargramostim 1pegylated granulocyte colony-stimulating factor 1ixabepilone 1etoposide phosphate 1aldesleukin 1Vincristine 1Vinblastine 1Taxes 1Sunitinib 1Standard of Care 1Second-Look Surgery 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Embryonal × Brentuximab Vedotin × Clear all
NCT02689219 2019-12-10

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

Indiana University

Phase 2 Terminated
18 enrolled 13 charts
Genitourinary

Nonseminomatous germ cell tumor, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

NCT01851200 2018-02-07

Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors

Fondazione Michelangelo

Phase 2 Completed
9 enrolled
Genitourinary

Neoplasm Metastasis, Neoplasms, Germ Cell and Embryonal, Testicular Neoplasms, Carcinoma, Embryonal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡